Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vyvgart effectiveness and safety in adults with myasthenia gravis
ChiCTR2400080921Phase 4Recruiting
- Sponsor
- Shijiazhuang People’s Hospita
- Start
- Feb 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of efgartigimod alfa in myasthenia gravis (MG) (8 arms), sponsored by Shijiazhuang People’s Hospita. Primary endpoints: Quantitative Myasthenia Gravis score at Day 28 and Activities of daily living at Day 28. Started Feb 2024; status: recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on ChiCTR2400080921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080921.